Aichun, Shu – Trademark Portfolio

Entity Type: 01

Aichun, Shu holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include EKANG, FEVOR, and HUAEN. The owner is based in Huaihua City, Hunan.

Group 1, Dongtingxi Village

Qinglang Township, Yuanling County

Huaihua City, Hunan 419633 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EKANG
EKANG
Registered 2020
HUAEN
HUAEN
Registered 2020
FEVOR
FEVOR
Registered 2020

Trademark Classifications

Aichun, Shu's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Aichun, Shu have?

Aichun, Shu has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Aichun, Shu file in?

Aichun, Shu files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Aichun, Shu's most well-known trademarks?

Aichun, Shu's registered trademark portfolio includes well-known marks such as EKANG, FEVOR, and HUAEN. These are among 3 currently registered trademarks in the portfolio.

What is Aichun, Shu's trademark registration success rate?

Aichun, Shu has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.